

Thank you for your interest in the CELESTIAL study.

If you have a specific form of liver cancer, the global phase 3 CELESTIAL clinical trial may be an option for you. This study is investigating a therapy called cabozantinib for the treatment of advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, in adults whose disease has spread or grown after treatment with the medication sorafenib (Nexavar®).




What is the CELESTIAL clinical trial?

The CELESTIAL global phase 3 clinical trial will test the effects of cabozantinib compared with placebo in patients with advanced HCC who have already received treatment with sorafenib (Nexavar®), another medication used for HCC treatment. The main purpose of the CELESTIAL trial is to determine whether cabozantinib can improve patient survival.

What is the study design?

CELESTIAL is a double-blind global phase 3 study, which means neither the patients nor the physicians know who is getting a placebo and who is getting the test drug. Patients will be randomly assigned to receive either cabozantinib 60 mg tablet once daily or a placebo. Two-thirds of the patients will receive cabozantinib, and one-third will receive a placebo.

The study is being conducted globally at more than 100 sites in 19 countries. You can learn more about the sites at <https://clinicaltrials.gov/ct2/show/NCT01908426>.



Who can participate in the study?

- You may be able to participate in the study if you:
 - are 18 years or older
 - have been diagnosed with advanced HCC
 - your HCC has spread or grown following at least one prior cancer medication
 - have received prior sorafenib (Nexavar®) treatment
 - have received up to two prior systemic cancer therapies for HCC
 - have adequate liver function
- Other eligibility criteria will apply
- More detailed eligibility criteria can be found here at <https://clinicaltrials.gov/ct2/show/NCT01908426>.

What can I expect if I participate in the study?

- If you are interested in participating, you will be asked to come to the study site for tests to determine whether you qualify for the study. This is called the screening visit.
- If you qualify and agree to participate in the study, you will be assigned randomly to one of the following groups:

GROUP 1	Oral cabozantinib 60 mg tablet once daily	GROUP 2	A placebo tablet once daily
		The placebo is a “sugar pill” that does not contain active medicine, but it will look exactly like the medicine being tested.	
Neither you nor the study doctor will know which of the two tablets you will be taking.			

- Two-thirds of the patients will receive cabozantinib, and one-third will receive a placebo.
- You will return to the clinic every few weeks to check if your tumor is responding to the therapy and to manage any side effects you might experience from the treatment.

How do I enroll in the study?

- Speak with your doctor to see whether he or she thinks this study may be a good option for you.
- To find study sites or referrals to doctors who are running the trial at medical centers that might be close to you, you may call 1-855-292-3935, email medinfo@exelixis.com or visit <https://clinicaltrials.gov/ct2/show/NCT01908426> to learn more.

What medicine is being studied in the CELESTIAL clinical trial?

- This trial studies cabozantinib, an oral prescription medication currently used to treat people with advanced kidney cancer who have received prior treatment.
 - Please see additional Important Safety Information below and the full Prescribing Information for CABOMETYX at <https://cabometyx.com/downloads/CABOMETYXUSPI.pdf>.
- Cabozantinib belongs to a class of drugs called tyrosine kinase inhibitors and binds to certain protein receptors on cells known as MET, AXL and VEGFR-1, -2 and -3. These receptors may play a role in how tumors grow and spread in the body. By binding to these receptors, cabozantinib may stop tumors from growing.
- You might be assigned to receive a placebo (sugar pill) tablet. Neither you nor the study doctor will be able to tell which medication you are receiving.
- Cabozantinib has not been approved for the treatment of liver cancer.

What are the side effects associated with cabozantinib?

- All medications have side effects. A full list of the cabozantinib side effects can be seen in the full Prescribing Information at <https://cabometyx.com/downloads/CABOMETYXUSPI.pdf>.
- You may experience side effects other than those listed in the full Prescribing Information.

Visit www.celestialclinicaltrial.com, call 1-855-292-3935 or email medinfo@exelixis.com to learn more about this trial.